New Guaiane-Type Sesquiterpenoid Glycosides from *Torillis japonica* Fruit

Junichi Kitajima,* Nobuyuki Suzuki, and Yasuko Tanaka

Showa College of Pharmaceutical Sciences, Higashi-Tamagawagakuen 3, Machida, Tokyo 194–8543, Japan. Received April 14, 1998; accepted August 15, 1998

From the water-soluble portion of the methanolic extract of *Torillis japonica* D. C. fruit (Umbelliferae), nine new guaiane-type sesquiterpenoid glycosides, including three kessane derivatives, have been isolated. Their structures were clarified by spectral and chemical investigations.

Key words Torillis japonica fruit; sesquiterpenoid glycoside; guaiane; kessane; torilolone; Umbelliferae

In a previous paper,¹⁾ we reported the isolation and characterization of a hemiterpenoid polyol and monoterpenoid glycoside from the fruit of *Torillis japonica* D. C. [Japanese name "Yabujirami" (Umbelliferae)]. In this paper, we describe nine new glycosides of guaiane-type sesquiterpenoids, which were isolated from a water-soluble fraction, as described in the Experimental section. All glycosides obtained in this paper were β -D-glucopyranosides, as evidenced from their ¹³C-NMR data (Table 2), and by enzymatic hydrolysis to yield D-glucose. Their molecular formulae were suggested from the accurate mass number of [M+H]⁺ or [M+Na]⁺ ion peaks in high-resolution positive FAB-MS.

Enzymatic hydrolysis of glycoside 1 ($C_{21}H_{34}O_8$, an amorphous powder, $[\alpha]_D^{21} - 36.4^\circ$) gave an aglycone (1a, $C_{15}H_{24}O_3$) and D-glucose. The aglycone was identical with torilolone, which was obtained by the alkaline hydrolysis of torilin.²⁾ The position of the glucosyl unit was deduced to be C-11 from the observed three bond correlation between the anomeric proton and the C-11 carbon signal in the heteronuclear multiple-bond correlation (HMBC) spectrum. Therefore, 1 could be represented as torilolone 11-O- β -D-glucopyranoside

Glycoside **2** ($C_{21}H_{32}O_8$, an amorphous powder, $[\alpha]_2^{21} + 5.1^\circ$) was revealed to be an 8-oxo derivative of **1** by comparison of its 1H - and ^{13}C -NMR data with those of **1** (Tables 1, 2). This was confirmed by enzymatic hydrolysis which gave aglycone **2a** ($C_{15}H_{22}O_3$), which was identical with the CrO_3 oxidation product of **1a**. Therefore, **2** was characterized as (1R,7R,10S)-11-hydroxyguai-4-ene-3,8-dione β -D-glucopyranoside.

Glycosides 3 ($C_{23}H_{36}O_9$, mp 228—230°C, $[\alpha]_D^{21} - 18.3$ °) and 4 ($C_{23}H_{36}O_9$, an amorphous powder, $[\alpha]_D^{21} + 22.0$ °) showed, in addition to a glucopyranoside moiety, three *tert*-methyls, one *sec*-methyl, three methylenes, four methines (one of them oxygenated), one tetrasubstituted double bond, one carbonyl function, one acetoxy group, and one oxygenated quaternary carbon, in their 1 H- and 13 C-NMR data (Tables 1, 2). These data and the results of HMBC experiments suggested that they had planar structures analogous to 1. Alkaline hydrolysis of 3 using 7% NH₄OH–MeOH gave a deacetate derivative ($\bf 5$, $C_{21}H_{34}O_8$), and enzymatic hydrolysis of $\bf 5$ gave an aglycone ($\bf 5a$, $C_{15}H_{24}O_3$) and D-glucose. Aglycone $\bf 5a$ was not identical with $\bf 1a$, but the diketone derivatives obtained by CrO_3 oxidation of $\bf 1a$ and $\bf 5a$ were identical. Thus, $\bf 5a$ was suggested to be a 8-epimer of $\bf 1a$. This suggestion was supported by the downfield shifts of H-7 α (by

 $0.40 \, \mathrm{ppm}$) and H-10 α (by 0.75 ppm), and by the upfield shift of the H₃-12 signal (by 0.17 ppm) of 5a, when compared with those of 1a. The position of the glucosyl and acetoxy units in 3 were ascertained to be C-8 and C-11, respectively, by the observed three bond correlation between the anomeric proton and the C-8 carbon in the HMBC spectrum, and the downfield shift of the C-11 signal (by 11.6 ppm), when compared with 5a. The absolute configuration at C-8 was deduced to be S by the glycosylation shift ($\Delta \delta$ 3—5a: 9.72 ppm) and the chemical shift of the glucosyl C-1 signal $(\delta 104.96)$. Thus, 3 was characterized as 11-O-acetyl-8-epitorilolone 8-O- β -D-glucopyranoside. Glycoside 4 was a stereoisomer of 3. Nuclear Overhauser effect (NOE) interactions between the proton signals shown in Fig. 1 were observed in the nuclear Overhauser and exchange spectroscopy (NOESY) spectrum of 4, and the configurations at H-1, H-7 and H-10 were concluded to be α , while H-8 was β . Further, the absolute configuration at C-8 was suggested to be S by comparison of the chemical shifts of the C-8 and glucosyl C-1 carbons with those of 3 [C-8 (3: δ 79.95, 4: δ 81.48), glucosyl C-1 (3: δ 104.96, 4: δ 104.77)]. Therefore, 4 was characterized as (1S,7R,8S,10S)-11-acetoxy-8-hydroxyguai-4-en-3-one 8-O- β -D-glucopyranoside.

Glycoside **5** ($C_{21}H_{34}O_8$, an amorphous powder, $[\alpha]_D^{21} - 5.1^\circ$) was identical with the material obtained by alkaline hydrolysis of **3**. Therefore, **5** was identified as 8-*epi*-torilolone 8-O- β -D-glucopyranoside.

Glycoside 6 ($C_{21}H_{36}O_9$, mp 228—230 °C, $[\alpha]_D^{21} +6.7^\circ$) showed the presence of three *tert*-methyls, one *sec*-methyl, three methylenes, five methines (two of them oxygenated) and three oxygenated quaternary carbons in the aglycone moiety by ¹H- and ¹³C-NMR data (Tables 1, 2). Enzymatic hydrolysis gave an aglycone ($\bf 6a$, $C_{15}H_{26}O_4$) and D-glucose. From analysis of the HMBC and $^1H^{-1}H$ correlated spectroscopy (COSY) spectral data for 6a, a gross planar structure was obtained and was suggested to be a guaiane-type sesquiterpenoid with oxygenated functions at C-2, C-7, C-8, C-10 and C-11. From the molecular formula, 6a was suggested to have a kessane skeleton having an ether ring between C-10 and C-11.4) This was also supported by the observed NOE interactions between the proton signals shown in Fig. 1 in the NOESY spectra of **6a** and **6a**-diacetate (**6a**'). The configurations at H-2 and H-8 were indicated to be β and α , respectively, from the observed NOE interactions between H-2 and H₃-14, H-2 and H-5 β , H-1 α and H-8, and between H-6 α and H-8. Thus, **6a** was characterized as

© 1998 Pharmaceutical Society of Japan

1744 Vol. 46, No. 11

Table 1. H-NMR Chemical Shifts of 1—9, 1a, 2a and 5a—7a [in Pyridine-d₅ Except 2a (in CDCl₃), 500 MHz]

| | 1 | 1a | 2 | 2a | | |
|--------------------|---------------------------|---------------------------|------------------------------------|------------------------------------|--|--|
| H-1 | 2.24 m | 2.24 m | 2.35 br dd (13.5, 7.0) | 2.48 br dd (11.0, 6.5) | | |
| $H-2\alpha$ | 2.09 dd (18.0, 3.5) | 2.06 dd (18.0, 3.5) | 2.03 dd (18.0, 1.5) | 2.08 dd (18.5, 1.5) | | |
| 2β | 2.56 dd (18.0, 6.0) | 2.59 dd (18.0, 6.0) | 2.54 dd (18.0, 7.0) | 2.63 dd (18.5, 6.5) | | |
| Η-6α | 3.19 br d (13.0) | 3.09 br d (13.5) | 3.20 dd (13.0, 5.0) | 3.07 dd (12.0, 4.0) | | |
| 6β | 2.67 dd (13.0, 10.0) | 2.64 dd (13.5, 9.5) | 2.95 dd (13.0, 13.0) | 2.56 dd (13.0, 13.0) | | |
| H-7 | 1.67 br dd (10.0, 4.0) | 1.42 br dd (9.5, 4.5) | 2.73 dd (13.0, 5.0) | 2.35 dd (13.0, 4.0) | | |
| H-8 | 4.49 ddd (10.0, 7.5, 4.0) | 4.53 ddd (10.0, 8.0, 4.0) | | | | |
| H-9 α | 2.18 br dd (14.0, 7.5) | 2.16 dd (14.0, 8.0) | 3.35 ^{a)} dd (12.0, 12.0) | 2.99 ^{a)} dd (12.0, 12.0) | | |
| 9β | 1.89 m | 1.95 m | 2.29 ^{a)} dd (12.0, 2.0) | 2.36 ^{a)} dd (12.0, 2.0) | | |
| H-10 | 1.24 m | 1.20 m | 1.36 m | 1.47 m | | |
| H ₃ -12 | 1.78 s | 1.66 s | 1.63 s | $1.30^{b)}$ s | | |
| H_3-13 | 1.69 s | 1.50 s | 1.64 s | $1.33^{h)}$ s | | |
| H ₃ -14 | 0.89 d (6.5) | 0.91 d (6.5) | 0.91 d (6.5) | 1.15 d (6.5) | | |
| H ₃ -15 | 1.79 d (1.5) | 1.82 d (1.5) | 1.69 s | 1.70 s | | |
| Glc-1 | 5.17 d (7.5) | | 5.08 d (8.0) | | | |
| OAc | • • | | | | | |

| | 3 | 4 | 5 | 5a | | |
|--------------------|---------------------------|---------------------------|------------------------|--------------------------|--|--|
| H-1 | 2.21 m | 2.52 m | 2.20 m | 2.21 m | | |
| $H-2\alpha$ | 1.94 dd (18.0, 2.0) | 2.54 dd (17.0, 6.0) | 1.94 dd (18.0, 2.0) | 2.10 dd (18.5, 3.0) | | |
| 2β | 2.55 dd (18.0, 6.0) | 2.03 br d (17.0) | 2.54 dd (18.0, 6.5) | 2.61 dd (18.5, 7.5) | | |
| Η-6α | 2.85 br dd (12.5, 2.5) | 2.74 dd (17.0, 5.0) | 2.82 br d (13.0) | 2.79 br d (12.5) | | |
| 6β | 2.13 dd (13.5, 12.5) | 2.69 dd (17.0, 8.0) | 2.10 dd (13.0, 13.0) | 2.01 dd (12.5, 11.5) | | |
| H-7 | 2.43 ddd (13.5, 4.0, 2.5) | 2.90 ddd (8.0, 5.0, 5.0) | 2.03 br dd (13.0, 4.5) | 1.82 dd (11.5, 7.5) | | |
| H-8 | 4.22 br dd (5.0, 4.0) | 4.26 br dd (8.0, 4.0) | 4.45 br dd (4.5, 3.5) | 4.43 ddd (7.5, 3.5, 3.5) | | |
| H-9 α | 2.53 br dd (14.5, 5.0) | 2.36 ddd (14.5, 4.0, 4.0) | 2.47 dd (14.5, 4.5) | 2.02 dd (13.0, 3.5) | | |
| 9β | 1.79 m | 2.30 dd (14.5, 7.0) | 1.85 m | 1.97 dd (13.0, 3.5) | | |
| H-10 | 2.00 m | 1.43 m | 1.94 m | 1.95 m | | |
| H ₃ -12 | 1.89 s | 1.86 s | 1.46 s | 1.49 s | | |
| H ₃ -13 | 1.64 s | 1.71 s | 1.52 s | 1.53 s | | |
| H ₃ -14 | 1.09 d (6.5) | 1.17 d (6.5) | 1.05 d (6.5) | 0.96 d (6.5) | | |
| H ₃ -15 | 1.78 d (1.5) | 1.86 s | 1.76 d (1.5) | 1.80 d (1.5) | | |
| Glc-1 | 4.86 d (7.5) | 5.20 d (7.5) | 4.94 d (8.0) | . , | | |
| OAc | 2.06 s | 2.00 s | ` ' | | | |

 2α ,7,8 β -trihydroxykessane. The position of the glucosyl unit in **6** was ascertained to be C-2 from the observed three bond correlation between the anomeric proton and the C-2 carbon signal in the HMBC spectrum, and the absolute configuration at C-2 was suggested to be S for the same reasons described for **3** [C-2 (δ 83.11, $\Delta\delta$ **6**—**6a**: 10.23 ppm), glucosyl C-1 (δ 105.54)]. Thus, **6a** was confirmed to have the same absolute configuration as kessane. From these facts, **6** could be represented as 2α ,7,8 β -trihydroxykessane 2-O- β -D-glucopyranoside.

Glycosides 7 ($C_{21}H_{36}O_8$, an amorphous powder, $[\alpha]_D^{21}+17.6^\circ$) and 8 ($C_{21}H_{36}O_9$, an amorphous powder, $[\alpha]_D^{23}+10.0^\circ$) were revealed to be derivatives of 6 by comparison of 1H - and ^{13}C -NMR data (Tables 1, 2), and HMBC experiments. Enzymatic hydrolysis of 7 gave an aglycone (7 a, $C_{15}H_{26}O_3$) and D-glucose. Comparison of the ^{13}C -NMR data for 6 a and 7 a suggested that 7 a was an 8-dehydroxyl derivative of 6 a. The observed NOE interactions, shown in Fig. 1, in the NOESY spectrum of 7 a supported this conclusion. In glycoside 8, the presence of a hydroxymethyl group was shown by the 1 H- and ^{13}C -NMR data. Further, 8 was indicated to be the 12-hydroxy derivative of 7 by comparison of ^{13}C -NMR data, and the observed NOE interactions between H-5 6 a and H₃-13, and between H-6 6 a and H₃-13 (Fig. 1) in the NOESY spectrum. As the absolute configurations at C-2 of 7

and **8** were indicated to be S [C-2 (7: δ 83.44, $\Delta\delta$ 7—7a: 10.39 ppm, **8**: δ 83.38), glucosyl C-1 (7: δ 105.68, **8**: δ 105.65)], they were revealed to have the same absolute configuration as **6**. Thus, **7** and **8** were characterized as 2α ,7-dihydroxykessane 2-O- β -D-glucopyranoside and 2α ,7,12-trihydroxykessane 2-O- β -D-glucopyranoside, respectively.

Glycoside 9 ($C_{21}H_{38}O_8$, an amorphous powder, $[\alpha]_D^{21}$ +9.8°) showed the presence of three tert-methyls, six methylenes (one of them oxygenated), four methines (one of them oxygenated) and two oxygenated quaternary carbons, in the ¹H- and ¹³C-NMR data (Tables 1, 2). From analysis of the HMBC and ¹H–¹H COSY spectral data, the aglycone of 9 was suggested to be a guaiane-type sesquiterpenoid having three hydroxyl groups at C-10, C-11 and C-15. The position of the glucosyl unit was indicated to be C-2 from the observed three bond correlation between the anomeric proton and C-2 carbon signals. The configurations at C-1, C-4, C-5, C-7 and C-10 were deduced to be the same as kessane from the observed NOE interactions in its NOESY spectrum, as shown in Fig. 1. Though the absolute configuration of 9 could not be deduced from the above data, it can be drawn as shown in Fig. 1 from a biogenetic point of view. From these results, **9** was concluded to be (1R,4R,5R,7R,10S)-10,11,15trihydroxyguaiane 11-O- β -D-glucopyranoside.

Glycosides 6—8 have aglycones having structures that are

Table 1. Continued

| | 6 | 6a | 7 |
|--|-------------------------------|---------------------------|----------------------------|
| H-1 | 2.20 dd (14.0, 9.0) | 2.14 dd (13.0, 9.0) | 2.23 dd (13.5, 9.0) |
| Η-2α | | , , , | , , , |
| 2β | 4.11 ddd (9.0, 9.0, 5.0) | 4.35 ddd (9.0, 9.0, 6.0) | 4.15 ddd (9.0, 9.0, 5.0) |
| Η-3α | 1.76 br dd (14.0, 5.0) | 1.44 ddd (14.0, 6.0, 2.5) | 1.80 ddd (15.0, 5.0, 2.5) |
| 3β | 2.58 ddd (14.0, 9.0, 9.0) | 2.52 ddd (14.0, 9.0, 9.0) | 2.61 ddd (15.0, 9.0, 9.0) |
| H-4 ['] | 1.90 m | 2.00 m | 1.91 bd dd (15.0, 13.0) |
| H-5 | 2.39 br ddd (14.0, 13.0, 9.0) | 2.53 m | 2.41 ddd (13.0, 13.0, 7.0) |
| Η-6α | 1.79 bd d (13.0) | 1.87 dd (13.5, 13.5) | 1.92 br d (13.0) |
| 6β | 2.30 dd (13.0, 7.0) | 2.38 dd (13.5, 6.5) | 2.25 dd (13.0, 13.0) |
| Η-8α | 4.21 m | 4.36 dd (9.0, 8.0) | 2.02 m |
| 8β | | | 2.27 br dd (13.0, 5.0) |
| H-9α | 2.35 br d (2H, 8.5) | 2.61 dd (13.5, 9.0) | 1.78 ddd (13.0, 7.0, 5.0) |
| 9β | , , , | 2.48 dd (13.5, 8.0) | 2.03 m |
| H ₃ - or H ₂ -12 | 1.68 s | 1.74 s | 1.56 s |
| H ₃ -13 | 1.54 s | 1.57 s | 1.55 s |
| H ₃ -14 | 1.77 s | 1.76 s | 1.75 s |
| H ₃ - or H ₂ -15 | 0.84 d (7.0) | 0.95 d (7.5) | 0.90 d (7.0) |
| Glc-1 | 4.79 d (6.5) | • | 4.82 d (8.0) |

| | 7a | 8 | 9 | | |
|--|-------------------------------|----------------------------|--------------------------------|--|--|
| H-1 | 2.16 dd (14.0, 8.5) | 2.23 dd (13.0, 9.0) | 1.79 br dd (9.0, 9.0) | | |
| $H-2\alpha$ | | | 1.96 m | | |
| 2β | 4.37 ddd (9.0, 8.5, 6.0) | 4.16 ddd (9.0, 9.0, 5.0) | 1.81 br dd (9.0, 9.0) | | |
| Η-3α | 1.49 ddd (13.5, 5.5, 2.5) | 1.80 ddd (15.0, 5.0, 2.5) | 1.71 br ddd (12.0, 12.0, 4.0) | | |
| 3β | 2.55 ddd (14.0, 9.0,9.0) | 2.61 ddd (15.0, 9.0, 9.0) | 1.97 m | | |
| H-4 | 2.03 m | 1.93 br dd (9.0, 6.5) | 2.52 m | | |
| H-5 | 2.53 br ddd (14.0, 13.0, 7.0) | 2.44 ddd (19.5, 13.5, 6.5) | 2.95 dddd (9.0, 9.0, 8.0, 5.0) | | |
| Η-6α | 1.99 dd (13.0, 13.0) | 1.88 br d (13.5) | 1.86 m | | |
| 6β | 2.31 dd (13.0, 6.5) | 2.31 dd (19.5, 13.5) | 2.01 m | | |
| H-7 | | | 2.50 br t (9.0) | | |
| Η-8α | 2.17 m | 2.10 dd (12.0, 9.5) | 1.97 ddd (12.0, 12.0, 9.0) | | |
| 8β | 2.32 m | 2.30 dd (12.0, 9.5) | 2.14 m | | |
| H-9α | 1.82 ddd (10.0, 10.0, 4.0) | 1.59 br dd (13.0, 9.5) | 1.68 br dd (12.0, 12.0) | | |
| 9β | 2.13 m | 2.03 br dd (13.0, 9.5) | 2.12 br d (12.0) | | |
| H_3 - or H_2 -12 | 1.60 s | 3.90 br d (10.5) | 1.38 s | | |
| , 2 | | 4.29 br d (10.5) | | | |
| H ₃ -13 | 1.57 s | 1.78 s | 1.48 s | | |
| H ₃ -14 | 1.73 s | 1.73 s | 1.37 s | | |
| H ₃ - or H ₂ -15 | 1.01 d (7.0) | 0.90 d (7.5) | 3.87 dd (10.5, 8.0) | | |
| , 4 | • / | • • | 4.10 dd (10.5, 6.0) | | |
| Glc-1 | | 4.82 d (7.5) | 5.08 d (8.0) | | |

 δ in ppm from TMS [coupling constants (J) in Hz are given in the parentheses]. a,b) Assignments may be interchanged.

analagous to α -kessyl alcohol, which has strong antidepressant activity in mice. $^{6)}$

Experimental

The instruments and experimental conditions for obtaining spectral data and for chromatography were the same as in a previous paper.¹⁾

Extraction and Isolation of Guaiane-Type Sesquiterpenoid Glycosides The methanolic extract of the fruit of *Torillis japonica* D. C. was treated as described in a previous paper, ¹⁾ and the methanol eluate (11.1 g) was obtained from the aqueous portion (30.6 g) by Amberlite XAD-II chromatography. This fraction was chromatographed on Sephadex LH-20 (MeOH) to furnish five fractions (frs. 1—5). Fraction 2 (9.3 g) was purified by silica gel [CHCl₃-MeOH-H₂O (4:1:0.1→7:3:0.5→MeOH)] chromatography to afford seven fractions (frs. 2-1—2-7). From fr. 2-1, 3 (130 mg) and 4 (70 mg) were isolated by repeated Sephadex LH-20 (MeOH), Lobar RP-8 column [MeOH-H₂O (1:1)] and silica gel [CHCl₃-MeOH (9:1)] chromatographies. From fr. 2-2, 1 (18 mg), 2 (18 mg) and 5 (12 mg) were isolated by repeated Sephadex LH-20 (MeOH), Lobar RP-8 column [MeOH-H₂O (3:7)] chromatographies and HPLC [octadecyl silica (ODS), CH₃CN-H₂O (3:17 and 1:5)]. From fr. 2-3, 7 (159 mg) was isolated by repeated Sephadex LH-20 (MeOH), Lobar RP-8 column [MeOH-H₂O (3:7)] and silica gel

[CHCl $_3$ -MeOH-H $_2$ O (4:1:0.1)] chromatographies. From fr. 2-4, **6** (181 mg) was isolated by Sephadex LH-20 (MeOH), Lobar RP-8 column [MeOH-H $_2$ O (3:7)] and silica gel [CHCl $_3$ -MeOH-H $_2$ O (4:1:0.1)] chromatographies. From fr. 2-5, **8** (10 mg) and **9** (13 mg) were isolated by repeated Sephadex LH-20 (MeOH), Lobar RP-8 column [MeOH-H $_2$ O (3:7)], silica gel [CHCl $_3$ -MeOH-H $_2$ O (3:1:0.1) for **8**; CHCl $_3$ -MeOH-H $_2$ O (4:1:0.1) for **9**] chromatographies and HPLC [ODS, CH $_3$ CN-H $_2$ O (3:37) for **8**; ODS, CH $_3$ CN-H $_2$ O (1:9) for **9**].

Torilolone 11-*O*-β-b-Glucopyranoside (1) An amorphous powder, $[α]_D^{21}$ –36.4° (c=0.9, MeOH). Positive FAB-MS m/z: 415.2310 [M+H]⁺ (base, Calcd for C₂₁H₃₅O₈: 415.2332), 235 [M-C₆H₁₂O₆+H]⁺.

Enzymatic Hydrolysis of 1 A mixture of 1 (10 mg) and hesperidinase (3 mg) in water (5 ml) was shaken on a water bath at 37 °C for two weeks. The mixture was evaporated *in vacuo* to dryness and the residue was chromatographed on silica gel [CHCl₃–MeOH (9:1) and CHCl₃–MeOH–H₂O (7:3:0.5)] to give torilolone (1a; 4 mg) and the sugar fraction. The sugar fraction was passed through Sephadex LH-20 (MeOH) to give a syrup. This was analyzed by HPLC [column; carbohydrate analysis (Waters: size, 3.9×300 mm), detector; JASCO RI-930 and OR-990 chiral detector: CH₃CN–H₂O (17:3), 2 ml/min; t_R 4.53 min] which revealed the presence of p-glucose.

Torilolone (1a) Colorless needles (aq. MeOH), mp 180—182 °C, $[\alpha]_D^{21}$

1746 Vol. 46, No. 11

Table 2. 13 C-NMR Chemical Shifts of 1—9, 1a, 2a and 5a—7a [in Pyridine- d_5 Except 2a (in CDCl₃), 125 MHz]

| | 1 | 1a | 2 | 2a | 3 | 4 | 5 | 5a | 6 | 6a | 7 | 7a | 8 | 9 |
|--------------|--------|--------|--------|--------|---------------|---------------|--------|--------|--------|-------|--------|-------|--------|-------|
| Aglycone C-1 | 51.84 | 51.89 | 50.17 | 50.17 | 50.11 | 48.34 | 50.23 | 50.89 | 54.66 | 56.32 | 55.24 | 56.97 | 55.31 | 54.44 |
| C-2 | 41.57 | 41.57 | 41.82 | 41.50 | 41.84 | 41.99 | 41.71 | 41.64 | 83.11 | 72.85 | 83.44 | 73.07 | 83.38 | 28.9 |
| C-3 | 207.83 | 207.79 | 207.11 | 207.61 | 207.90 | 207.44 | 207.87 | 207.66 | 42.50 | 44.13 | 42.74 | 44.36 | 42.63 | 29.6 |
| C-4 | 134.21 | 133.85 | 138.37 | 138.36 | 135.89 | 136.20 | 135.30 | 134.76 | 32.23 | 31.76 | 32.41 | 31.88 | 32.39 | 47.3 |
| C-5 | 176.60 | 176.78 | 172.43 | 171.30 | 175.43 | 174.98 | 176.32 | 176.27 | 38.18 | 38.83 | 38.50 | 39.11 | 38.12 | 36.4 |
| C-6 | 24.75 | 24.83 | 27.15 | 27.63 | 28.12 | 27.83 | 29.28 | 28.77 | 40.18 | 40.43 | 42.74 | 43.00 | 43.02 | 27.4 |
| C-7 | 50.84 | 49.50 | 60.51 | 59.49 | 52.39 | 51.81 | 54.19 | 54.98 | 71.68 | 71.79 | 71.53 | 71.59 | 72.61 | 47.4 |
| C-8 | 68.84 | 69.90 | 213.13 | 214.54 | 79.95 | 81.48 | 81.45 | 70.23 | 71.93 | 72.10 | 33.57 | 33.70 | 34.06 | 21.6 |
| C-9 | 44.65 | 44.57 | 49.83 | 50.12 | 39.48 | 40.07 | 39.92 | 43.26 | 47.79 | 48.37 | 36.91 | 37.41 | 37.21 | 46.4 |
| C-10 | 33.44 | 33.60 | 41.56 | 39.86 | 33.30 | 37.54 | 33.11 | 32.31 | 72.89 | 72.95 | 73.94 | 73.95 | 74.37 | 71.2 |
| C-11 | 80.53 | 73.05 | 78.42 | 72.22 | 84.92 | 85.00 | 72.64 | 73.29 | 78.38 | 78.40 | 78.61 | 78.59 | 78.75 | 81.4 |
| C-12 | 24.41 | 28.91 | 25.06 | 27.23 | 22.90 | 24.16 | 26.08 | 26.01 | 25.80 | 25.89 | 24.87 | 24.92 | 69.93 | 22.8 |
| C-13 | 26.89 | 29.51 | 25.68 | 28.62 | 24.57 | 25.76 | 29.61 | 29.41 | 28.32 | 28.18 | 27.77 | 27.84 | 20.33 | 24.5 |
| C-14 | 23.09 | 23.06 | 22.60 | 22.83 | 23.02 | 23.29 | 23.15 | 23.44 | 28.56 | 28.48 | 28.67 | 28.24 | 28.32 | |
| C-15 | 8.25 | 8.13 | 7.78 | 7.77 | 7.76 | 8.65 | 7.88 | 8.02 | 18.21 | 18.71 | 18.20 | 18.75 | 18.11 | 62.8 |
| Glucose C-1 | 98.17 | | 98.57 | | 104.96 | 104.77 | 105.23 | | 105.54 | | 105.68 | | 105.65 | 98.5 |
| C-2 | 75.21 | | 75.27 | | 75.12 | 75.63 | 75.40 | | 75.40 | | 75.49 | | 75.49 | 75.4 |
| C-3 | 79.07 | | 78.24 | | 78.30 | 78.36 | 78.42 | | 78.07 | | 78.16 | | 78.20 | 78.0 |
| C-4 | 71.98 | | 71.81 | | 71.50 | 71.97 | 71.55 | | 71.83 | | 71.92 | | 71.92 | 71.9 |
| C-5 | 78.38 | | 78.88 | | 78.65 | 78.67 | 78.58 | | 78.52 | | 78.61 | | 78.62 | 78.6 |
| C-6 | 63.02 | | 62.89 | | 62.88 | 63.12 | 62.85 | | 62.98 | | 63.05 | | 63.07 | 63.0 |
| OAc | | | | | 22.56, 170.19 | 22.52, 170.17 | | | | | | | | |

 δ in ppm from TMS.




Fig. 1. Structures of 1—9 and NOE Interactions Observed in the NOESY Spectra of 4, 6a, 6a',7a and 9

 $-15.7^{\circ}~(c\!=\!0.3,~\text{MeOH})$ [lit.²) mp 179—180 °C, [\$\alpha\$] \$_D^{\,8}~-25.7^{\circ}~(c\!=\!1.83,~\text{CHCl}_3)\$].

(1R,7R,10S)-11-Hydroxyguai-4-ene-3,8-dione β -D-Glucopyranoside (2) Amorphous powder, $[\alpha]_{D}^{2l} + 5.1^{\circ}$ (c=0.7, MeOH). Positive FAB-MS m/z: 435 [M+Na]⁺, 413.2189 [M+H]⁺ (base, Calcd for $C_{21}H_{33}O_8$: 413.2176), 233 [M- $C_6H_{12}O_6+H$]⁺.

Enzymatic Hydrolysis of 2 A mixture of 2 (10 mg) was treated as described for 1, and the residue was chromatographed on silica gel [hexane—EtOAc (7:3) and $CHCl_3$ –MeOH– H_2O (7:3:0.5)] to give 2a (4 mg) and the sugar fraction. From the sugar fraction, the presence of D-glucose was demonstrated as for 1.

(1R,7R,10S)-11-Hydroxyguai-4-ene-3,8-dione (2a) An amorphous powder, $[\alpha]_D^{21}$ +20.8° (c=0.3, MeOH). Positive FAB-MS m/z: 252 [M+H]⁺ (base; $C_{15}H_{23}O_3$).

CrO₃ Oxidation of 1a A mixture of torilolone (20 mg), acetic acid (5 ml) and CrO₃ (5 mg) was stirred for 3 h at room temperature. The reaction mixture was then poured into water and extracted with Et₂O. The organic layer was concentrated to give a residue, which was purified by silica gel [hexane–EtOAc (7:3)] chromatography and HPLC [ODS, CH₃CN–H₂O (9:1)] to give 2a (5.5 mg).

11-*O*-Acetyl-8-*epi*-torilolone 8-*O*-β-D-Glucopyranoside (3) Colorless needles (aq. MeOH), mp 228—230 °C, $[\alpha]_D^{21} - 18.3^\circ$ (c=1.5, MeOH). Positive FAB-MS m/z: 913 $[2M+H]^+$, 457.2466 $[M+H]^+$ (Calcd for $C_{23}H_{37}O_6$: 457.2437), 397 $[M-CH_3COOH+H]^+$, 295 $[M-C_6H_{10}O_5+H]^+$ (base), 277 $[M-C_6H_{12}O_6+H]^+$, 235 $[M-CH_3COOH-C_6H_{10}O_5+H]^+$.

Deacetylation of 3 3 (30 mg) was refluxed in 7% NH₄OH–MeOH on a hot water bath for 21 h, then the reaction mixture was evaporated *in vacuo* to dryness and the residue chromatographed on silica gel [CHCl₃–MeOH–H₂O (4:1:0.1)] and Sephadex LH-20 (MeOH) to give 5 (20 mg).

Enzymatic Hydrolysis of 5 A mixture of 5 (19 mg) and hesperidinase (5 mg) in water (5 ml) was shaken on a water bath at 37 °C for two weeks. The mixture was evaporated *in vacuo* to dryness and the residue was chromatographed on silica gel [hexane–EtOAc (3:2) and $CHCl_3$ –MeOH–H₂O (7:3:0.5)] to give 3a (8 mg) and the sugar fraction. From the sugar fraction, the presence of p-glucose was demonstrated as for 1.

8-epi-Torilolone (3a) An amorphous powder, $[\alpha]_D^{23} - 27.7^{\circ}$ (c=0.7, MeOH). Positive FAB-MS m/z: 253 [M+H]⁺ (base; $C_{15}H_{25}O_3$).

 CrO_3 Oxidation of 3a A mixture of 3a (8 mg), acetic acid (2 ml) and CrO_3 (2 mg) was treated as described for 1a, and the residue was purified by silica gel [hexane–EtOAc (7:3)] chromatography and HPLC [ODS, CH_3CN-H_2O (9:1)] to give 2a (2.0 mg).

(1S,7*R*,8*S*,10*S*)-11-Acetoxy-8-hydroxyguai-4-en-3-one 8-*O*- β -D-Glucopy-ranoside (4) An amorphous powder, $[\alpha]_D^{23} + 22.0^{\circ}$ (c=1.0, MeOH). Positive FAB-MS m/z: 457.2458 [M+H]⁺ (Calcd for $C_{23}H_{37}O_9$: 457.2437), 397 [M-CH₃COOH+H]⁺, 295 [M-C₆H₁₀O₅+H]⁺ (base), 277 [M-C₆H₁₂O₆+H]⁺, 235 [M-CH₃COOH-C₆H₁₀O₅+H]⁺.

8-epi-Trilolone 8-O-β-D-Glucopyranoside (5) An amorphous powder, $[\alpha]_{\rm D}^{21}$ –5.1° (*c*=0.7, MeOH). Positive FAB-MS *m/z*: 437 [M+Na]⁺, 415.2317 [M+H]⁺ (base, Calcd for C₂₁H₃₅O₈: 415.2332), 235 [M-C₆H₁₀O₅+H]⁺.

2 α,7,8β-Trihydroxykessane 2-*O***-β-D-Glucopyranoside (6)** Colorless needles (aq. MeOH), mp 228—230 °C, $[α]_D^{21} + 6.7^\circ$ (c=2.0, MeOH). Positive FAB-MS m/z: 866 2[M+H]⁺, 433.2421 [M+H]⁺ (base, Calcd for $C_{21}H_{37}O_9$: 433.2438), 415 [M-H₂O+H]⁺, 379 [M-2H₂O+H]⁺, 253 [M- $C_6H_{12}O_6+H]^+$. Negative FAB-MS m/z: 431 [M-H]⁻ (base).

Enzymatic Hydrolysis of 6 A mixture of 6 (50 mg) and hesperidinase (5 mg) in water (5 ml) was shaken on a water bath at 37 °C for 30 d. The mixture was evaporated *in vacuo* to dryness and the residue was chromatographed on silica gel [hexane–EtOAc (3:2) and CHCl₃–MeOH–H₂O (7:3:0.5)] to give 6a (10 mg) and the sugar fraction. From the sugar fraction, the presence of p-glucose was demonstrated as for 1.

2 α ,7,8 β -Trihydroxykessane (6a) Colorless needles (aq. MeOH), mp 213—215 °C, $[\alpha]_{2}^{D1}$ +10.0° (c=0.5, MeOH). Positive FAB-MS m/z: 271.1901 [M+H]⁺ (Calcd for C₁₅H₂₇O₄: 271.1909), 253 [M-H₂O+H]⁺, 235 [M-2H₂O+H]⁺ (base), 217 [M-3H₂O+H]⁺. Negative FAB-MS m/z:

 $269 [M-H]^{-}$ (base).

Acetylation of 6a Aglycone 6a (5 mg) was acetylated with Ac₂O and pyridine at room temperature for 12 h to give a diacetate of 6a (6a': 6 mg) as an amorphous powder. ¹H-NMR (CDCl₃) δ: 0.93 (3H, d, J=7.5 Hz, H₃-15), 1.05 (1H, dddd, J=14.5, 5.5, 2.5 Hz, H-3α), 1.16 (3H, s, H₃-14), 1.26 (3H, s, H₃-13), 1.31 (3H, s, H₃-12), 1.71 (1H, br dd, J=13.5, 13.5 Hz, H-6α), 1.98 (1H, dd, J=14.5, 8.0 Hz, H-9β), 2,04 (1H, dd, J=13.5, 6.5 Hz, H-6β), 2.05 (1H, dd, J=13.5, 9.5 Hz, H-1), 2.06 (1H, m, H-4), 2.24 (1H, br ddd, J=13.5, 13.5, 6.5 Hz, H-5), 2.46 (1H, dd, J=14.5, 9.5 Hz, H-9α), 2.61 (1H, ddd, J=14.5, 9.0, 9.0 Hz, H-3β), 4.92 (1H, ddd, J=9.5, 9.0, 5.5 Hz, H-2), 4.98 (1H, dd, J=9.5, 8.0 Hz, H-8), 1.99, 2.13 (each 3H, s, OAc). ¹³C-NMR (CDCl₃) δ: 52.69 (C-1), 75.31 (C-2), 39.80 (C-3), 31.58 (C-4), 37.55 (C-5), 39.46 (C-6), 71.51 (C-7), 74.88 (C-8), 44.01 (C-9), 71.81 (C-10), 77.81 (C-11), 26.79 (C-12), 24.86 (C-13), 27.37 (C-14), 17.88 (C-15), acetoxyl [21.21, 21.28, 170.37, 170.50].

2α,7-Dihydroxykessane 2-*O*-**β**-D-Glucopyranoside (7) An amorphous powder, $[α]_D^{2l} + 17.6^\circ$ (c=1.4, MeOH). Positive FAB-MS m/z: 834 $2[M+H]^+$, 417.2487 $[M+H]^+$ (Calcd for $C_{21}H_{37}O_8$: 417.2489), 399 $[M-H_2O+H]^+$ (base), 237 $[M-C_6H_{12}O_6+H]^+$ Negative FAB-MS m/z: 415 $[M-H]^-$ (base).

Enzymatic Hydrolysis of 7 A mixture of 7 (50 mg) and hesperidinase (5 mg) in water (5 ml) was treated as described for 6, and the residue was chromatographed on silica gel [hexane–EtOAc (3:2) and CHCl₃–MeOH– $\rm H_2O$ (7:3:0.5)] to 7a (16 mg) and the sugar fraction. From the sugar fraction, the presence of p-glucose was demonstrated as for 1.

2 α ,7-Dihydroxykessane (7a) An amorphous powder, $[\alpha]_D^{21} + 11.6^{\circ}$ (c=0.4, MeOH). Positive FAB-MS m/z: 277 [M+Na]⁺, 255.1968 [M+H]⁺ (Calcd for C₁₅H₂₇O₃: 255.1960), 235 [M-H₂O+H]⁺ (base). Negative FAB-MS m/z: 253 [M-H]⁻ (base).

2α,7,12-Trihydroxykessane 2-*O***-β-D-Glucopyranoside (8)** An amorphous powder, $[α]_D^{23} + 10.0^\circ$ (c=0.8, MeOH). Positive FAB-MS m/z: 455.2252 [M+Na]⁺ (base, Calcd for C₂₁H₃₆O₉Na: 455.2257), 253 [M-C₆H₁₂O₆+H]⁺. Negative FAB-MS m/z: 431 [M-H]⁻ (base).

(1*R*,4*R*,5*R*,7*R*,10*S*)-10,11,15-Trihydroxyguaiane 11-*O*- β -D-Glucopyranoside (9) An amorphous powder, $[\alpha]_D^{21} + 9.8^\circ$ (*c*=1.3, MeOH). Positive FAB-MS *m/z*: 838 2[M+H]⁺, 441.2437 [M+Na]⁺ (Calcd for C₂₁H₃₈O₈Na: 441.2465), 419 [M+H]⁺, 401 [M-H₂O+H]⁺ (base), 239 [M-C₆H₁₂O₆+H]⁺. Negative FAB-MS *m/z*: 417 [M-H]⁻ (base).

Acknowledgments The authors thank Messrs. Y. Takase and H. Suzuki of the Central Analytical Department of Showa College of Pharmaceutical Sciences for NMR and MS measurements.

References and Notes

- Kitajima J., Suzuki N., Tanaka Y., Chem. Pharm. Bull., 46, 1583— 1586 (1998).
- Torilin was obtained as a main constituent of this methanolic extract;
 Chikamatsu M., Maeda M., Nakazaki M., Tetrahedron, 25, 4751—4765 (1969).
- Kasai R., Suzuo M., Asakawa J., Tanaka O., Tetrahedron Lett., 1977, 175—178; Tori K., Seo S., Yoshimura Y., Arita H., Tomita Y., ibid., 1977, 179—182; Kasai R., Okihara M., Asakawa J., Mizutani K., Tanaka O., Tetrahedron, 35, 1427—1432 (1979); Mizutani K., Kasai R., Tanaka O., Carbohydr. Res., 87, 19—23 (1980); Ishikawa T., Kitajima J., Tanaka Y., Ono M., Ito Y., Nohara T., Chem. Pharm. Bull., 46, 1738—1742 (1998).
- Nishiya K., Kimura T., Takeya K., Itokawa H., Phytochemistry, 31, 3511—3514 (1992).
- 5) Hikino H., Hikino Y., Takeshita Y., Isurugi Y., Takemoto T., Yakugaku Zasshi, 91, 650—656 (1971); Ito S., Kodama M., Nozoe T., Hikino H., Hikino Y., Takeshita Y., Takemoto T., Tetrahedron, 23, 553—563 (1967).
- Oshima Y., Matsuoka S., Ohizumi Y., Chem. Pharm. Bull., 43, 169— 170 (1995).